Skip to content

Retrospective analysis of the effectiveness and safety of endoscopic treatment for symptomatic hemorrhoids

Retrospective analysis of the effectiveness and safety of endoscopic treatment for symptomatic hemorrhoids

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500101874
Enrollment
Unknown
Registered
2025-04-30
Start date
2023-07-25
Completion date
Unknown
Last updated
2025-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemorrhoids

Interventions

rubber band ligation:NA
Shaobei injection:NA

Sponsors

The Sixth Affiliated Hospital, Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with grade I, II, III, and IV internal hemorrhoids accompanied by bleeding or prolapse; 2. Gender not limited, age between 18-100 years old; 3. Patients and their families understand and agree to participate in this study, and provide written informed consent to undergo sedation, analgesia/anesthesia, colonoscopy, and endoscopic hemorrhoid treatment.

Exclusion criteria

Exclusion criteria: 1. Patients who have received instrument therapy, including ligation and injection therapy, or surgical treatment, including hemorrhoidectomy, stapler hemorrhoid fixation, or transanal hemorrhoid artery ligation, within 3 months before the experiment; 2. Patients with acute episode of trapped hemorrhoids and/or thrombosis; 3. Patients with acute anal inflammation, anal fissure, anal fistula, perianal abscess, inflammatory bowel disease, etc.; 4. Patients with colon cancer or other cancers affecting treatment; 5. Severe immune dysfunction; 6. History of pelvic radiotherapy; 7. Pregnant or lactating women; 8. Patients with severe liver and kidney function, cardiopulmonary function, coagulation dysfunction, or severe underlying diseases, unstable condition, and unable to tolerate endoscopic surgery; 9. Patients with severe immune dysfunction; A history of mental illness; 10. Patients with other clinical or laboratory conditions that researchers believe are not suitable to participate in the trial.

Design outcomes

Primary

MeasureTime frame
Recurrence rate;effectiveness;

Secondary

MeasureTime frame
quality of life;patient satisfaction;

Countries

China

Contacts

Public ContactXuefeng Guo

The Sixth Affiliated Hospital, Sun Yat-sen University

guoxfeng@mail.sysu.edu.cn+86 138 2446 6151

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026